• Percent of Participants who Achieve Transfusion Independence [ Time Frame: Up to at least 56 days after initial administration of study drug ]
  Transfusion Independence: the rate of red blood cell (RBC) and platelet transfusion dependence (defined as having received ≥ 2 units of RBCs and/or platelets within 56 days prior to study) at baseline and assess transfusion independence, defined as at least 56 consecutive days without a RBC or platelet transfusion during the treatment period.
• Overall Response Rates (CR, CRi) [ Time Frame: Up to approximately 24 weeks ]
  Overall Response Rates to treatment is the proportion of participants who achieve complete remission or complete remission with incomplete hematologic recovery, based on guidelines adapted from the IWG for AML.

• Overall Response Rates (CR, CRi) [ Time Frame: Up to approximately 24 weeks ]
  Overall Response Rates to treatment is the proportion of participants who achieve complete remission or complete remission with incomplete hematologic recovery, based on guidelines adapted from the IWG for AML.
• Percent of Participants who Achieve Transfusion Independence [ Time Frame: Up to at least 56 days after initial administration of study drug ]
  Transfusion Independence: the rate of red blood cell (RBC) and platelet transfusion dependence (defined as having received ≥ 2 units of RBCs and/or platelets within 56 days prior to study) at baseline and assess transfusion independence, defined as at least 56 consecutive days without a RBC or platelet transfusion during the treatment period.

• Acute Myeloid Leukemia (AML)
• Cancer

• Drug: venetoclax
  tablet; oral
  Other Name: ABT-199
• Drug: azacytidine
  infusion; subcutaneous or intravenous
  Other Name: Vidaza
• Drug: decitabine
  infusion; intravenous
  Other Name: Dacogen

Inclusion Criteria:

• Participant has confirmation of acute myeloid leukemia (AML) by World Health Organization (WHO) criteria.
• Participant is deemed by the investigator to be an appropriate candidate for outpatient ramp-up of venetoclax.
• Participant is not eligible to receive treatment with standard cytarabine and anthracycline induction regimens.
• Participant has not received prior treatment for AML (treatment naïve) with the exception of hydroxyurea.
• Participant has no evidence of spontaneous tumor lysis syndrome (TLS) at Screening.
• Participant can have progressed from myelodysplastic syndrome (MDS) or be considered to have secondary AML and could have been treated with growth factors or other agents with the exception of hypomethylating agents.
• Participant has adequate kidney, liver and hematology laboratory values as detailed in the protocol.
• Has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 3.

Exclusion Criteria:

- Has a history of the following conditions:

• Acute promyelocytic leukemia
• Known active central nervous system involvement with AML
• Positive for HIV (HIV testing is not required)
• Positive for hepatitis B or C infection with the exception of those with an undetectable viral load within 3 months
• Cardiovascular disability status of New York Heart Association Class > 2
• Chronic respiratory disease that requires continuous oxygen or any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study
• Malabsorption syndrome or other condition that precludes enteral route of administration

Has a history of other malignancies within 2 years prior to study entry, with the exception of:

• Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast
• Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin
• Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent